J.B. Chemicals & Pharmaceuticals Q2FY26 Concall Decoded – Chronic Growth, Acute Calm, and a Dose of Margin Therapy
1. Opening Hook
Pharma companies usually blame monsoons, price caps, or “market conditions.” JB Pharma, meanwhile, just keeps dosing itself with margin steroids. While the rest of Indian pharma battled supply chain headaches, this 45-year-old midcap veteran pulled off another double-digit EBITDA growth and a gross margin that could make a Swiss drugmaker jealous. Chronic drugs kept the growth heartbeat steady even as the acute segment caught a cold. The story only gets juicier—especially when the CFO starts talking about ₹939 crore in cash and almost zero debt.
Stick around; this script has both chemistry and drama. 💊
2. At a Glance
Revenue up 8%: Outpacing India Pharma Market—because consistency is their new molecule.
Domestic sales up 9%: Chronic portfolio flexed its muscles while acute napped.
International up 7%: Russia smiled, South Africa sulked, and the US took a coffee break.
EBITDA up 12%: Margin magic at 29.4%—no placebo effect here.
PAT up 19%: Profit injections are working just fine.
Cash ₹939 crore, debt ₹7 crore: Balance sheet cleaner than a pharma lab floor.
3. Management’s Key Commentary
“J.B. Pharma delivered another quarter of good performance with revenues at ₹1,085 crore, up 8%.” (Translation: Beating benchmarks is now part of the dosage.)
“Gross margin improved by 200 bps to 68.2%.” (Translation: We cut costs faster than paracetamol cuts fever. 😏)
“Domestic business grew 9%, led by chronic portfolio up 20%.” (Translation: People may fall sick less, but lifestyle diseases never disappoint.)
“CDMO grew 20% year-on-year this quarter.” (Translation: Contract manufacturing—the real cash cow no one talks about.)
“We have ₹939 crore cash and only ₹7 crore debt.” (Translation: CFO sleeps like a baby while others chase working capital.)
“Ophthal portfolio perpetual license triggers from 2027, boosting margins further.” (Translation: Eyeing even higher profits—pun intended.) 👀
